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Despite intense efforts there is no safe and efficacious vaccine against visceral leishma-
niasis, which is fatal and endemic in many tropical countries. A major shortcoming in the
vaccine development against blood-borne parasitic agents such as Leishmania is the inad-
equate predictive power of the early immune responses mounted in the host against the
experimental vaccines. Often immune correlates derived from in-bred animal models do
not yield immune markers of protection that can be readily extrapolated to humans. The
limited efficacy of vaccines based on DNA, subunit, heat killed parasites has led to the
realization that acquisition of durable immunity against the protozoan parasites requires a
controlled infection with a live attenuated organism. Recent success of irradiated malaria
parasites as a vaccine candidate further strengthens this approach to vaccination.We devel-
oped several gene deletion mutants in Leishmania donovani as potential live attenuated
vaccines and reported extensively on the immunogenicity of LdCentrin1 deleted mutant
in mice, hamsters, and dogs. Additional limited studies using genetically modified live
attenuated Leishmania parasites as vaccine candidates have been reported. However, for
the live attenuated parasite vaccines, the primary barrier against widespread use remains
the absence of clear biomarkers associated with protection and safety. Recent studies
in evaluation of vaccines, e.g., influenza and yellow fever vaccines, using systems biol-
ogy tools demonstrated the power of such strategies in understanding the immunological
mechanisms that underpin a protective phenotype. Applying similar tools in isolated human
tissues such as PBMCs from healthy individuals infected with live attenuated parasites such
as LdCen−/− in vitro followed by human microarray hybridization experiments will enable
us to understand how early vaccine-induced gene expression profiles and the associated
immune responses are coordinately regulated in normal individuals. In addition, compara-
tive analysis of biomarkers in PBMCs from asymptomatic or healed visceral leishmaniasis
individuals in response to vaccine candidates including live attenuated parasites may pro-
vide clues about determinants of protective immunity and be helpful in shaping the final
Leishmania vaccine formulation in the clinical trials.
Keywords: Leishmania, vaccine, genetically modified organisms, live attenuated parasites, vaccine-induced
immunity, systems vaccinology, biomarkers of protection
INTRODUCTION
An estimated 100,000 VL cases are reported annually in the
endemic foci of northeastern India, Nepal, and Bangladesh alone
and ~150 million people are at risk for infection (1). The current
programs for elimination of VL include early diagnosis and treat-
ment, coordinated vector control, and effective disease surveillance
through passive and active case detection (2). Vector or reservoir
control, toxicity of currently available drugs, and increasing par-
asite resistance underline the need for an effective prophylactic
vaccine against leishmaniasis (3).
Estimates of potential economic value of a prophylactic vac-
cine indicated that even a vaccine with a relatively short duration of
protection and modest efficacy could prevent a substantial number
of cases at low-cost. Further, a vaccine providing ~5 years duration
of protection with as little as 50% efficacy remains cost–effective
compared with chemotherapy (4). Development of a prophylac-
tic vaccine against Leishmania has gone through a long trajectory
that includes phases of systematic selection of antigens, adjuvants,
natural immune parameters to identify correlates of protection
[reviewed in Ref. (5)]. Despite these advances, there is no effective
vaccine even though vaccine is thought to be feasible. Protection
against reinfection following a natural infection with Leishmania
major historically has been the reason for feasibility of a vaccine
(6). Similarly people successfully cured from visceral leishmaniasis
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develop Leishmania specific Th1-type cellular-mediated responses
and protection against new infections (7). The absence of an effec-
tive vaccine to a large extent is related to the absence of clear
understanding of correlates of protection. Concerns also remain
about the ability of current experimental models to predict pro-
tection against natural, sandfly transmitted infection (8). A recent
survey of past clinical trials with killed Leishmania antigens in
Central American countries, Iran, and Sudan showed absence of
efficacy against developing CL (3). This further underlines the lack
of understanding of the immune mechanisms that drive protec-
tion not only in human leishmaniasis but in other parasitic diseases
as well. This lack of vaccine efficacy owing to lack of knowledge of
correlates of protection is even more powerfully illustrated in the
recently concluded malaria vaccine trials where only a subpopula-
tion of the vaccines was protected (9). The parameters measured
in the vaccine study did not reveal any correlations that could
explain the observed differences. In contrast, tremendous progress
has been made in the understanding of vaccine-induced immu-
nity in several viral vaccines including AIDS (10), yellow fever (11),
and influenza (12) that showed the power of systematic analysis
of early immune responses can have immense value in providing
a clear understanding of immune mechanisms of protection.
BIOMARKERS OF ASYMPTOMATIC CARRIERS OF
VL-IMPLICATIONS TO VACCINE SUCCESS
In the Indian subcontinent, humans are the only reservoir of the
parasite L. donovani. An estimated 100,000 VL cases are reported
annually in the endemic foci of northeastern India, Nepal, and
Bangladesh, and in addition a significant number of asympto-
matic carriers also occur (13). Various epidemiologic studies have
reported that asymptomatic infections outnumber clinical VL
cases including in India and Nepal (9:1) and Bangladesh (4:1)
(14, 15). Thus, early diagnosis and treatment, and effective dis-
ease surveillance through passive and active case detection have
been identified as key components of Leishmania elimination (16).
Importantly, the asymptomatic carriers with no overt signs of
disease but could potentially develop active VL could serve as
reservoirs of parasites in the endemic areas. In practice, more
asymptomatic individuals than those with active VL are identified
in high endemicity areas (17). A 2-year longitudinal study in the
hyperendemic regions in India showed that seropositivity in direct
agglutination test (DAT)- and rK39-based tests at baseline cannot
predict development of VL (18). Persistence of antibodies over
periods of several years against L. donovani further complicates the
careful identification of active versus past exposure (19). In order
to develop biomarkers of parasitemia DAT, ELISA based on rK39
and whole cell lysate and quantitative PCR tests were employed
in a recent clinical study (20). Developing tools that can predict
progression to VL disease will lead to early intervention and treat-
ment, but also have implications for future vaccination trials. The
comparative diagnostic tests revealed the limited complementar-
ity between serology-based tests and DNA-based diagnostic assays
underlining the fact that the presence of L. donovani DNA is tran-
sient, as was also described in a larger survey of asymptomatic
children in Brazil (21). Further, the low predicted parasite bur-
den in the asymptomatic carriers in the study (the median 0.1 L.
donovani DNA equivalents/milliliter of blood) implied that more
robust PCR methods need to be developed to detect low parasite
burdens. In a whole blood-based IFN-γ release assay in high VL
endemic region in India showed that whole blood from active and
cured VL cases can produce antigen-specific IFN-γ (19). Secretion
of IFN-γ from active VL cases in whole blood assays strongly sug-
gested that no Th1 response deficit exists but the pathogenesis is
indicative of immune suppression. The only discriminating factor
between active and cured VL was IL-10 where only active VL cases
secreted IL-10 (13). This establishes a pattern of biomarkers that
will be helpful in a vaccine trial to identify asymptomatic carri-
ers and also raises important considerations for testing of in vitro
correlates in PBMCs versus whole blood cultures.
VACCINATION APPROACHES IN LEISHMANIA
Heat killed Leishmania and recombinant antigens have the longest
history of clinical trials against CL in parts of South America
including Brazil, Ecuador, and also in Iran and Sudan [reviewed
in Ref. (3)]. A majority of these trials used Leishmania skin test
(LST) as a biomarker for vaccine efficacy. This is due to a strong
correlation between LST positivity and protection after recovery
from the disease caused by several species (22). A retrospective
analysis indicated that reproducible evidence of protective efficacy
against CL has not emerged from these clinical trials using heat
killed Leishmania vaccines. Absence of demonstrable efficacy in
most of the randomized controlled trials is consistent with the
killed whole parasite preparations being inadequate to produce
long lasting, relevant immune responses required for protection.
Even though vaccinated groups in some trials showed larger LST,
the observed immunogenicity was not translated into protective
efficacy against CL. Thus measuring LST as a correlate of vaccine-
induced immunity has only limited predictive power. However,
conversion from negative LST reaction to LST>5 after vaccination
has been observed to be associated with significantly lower infec-
tion incidence in Brazil, Iran, and Sudan (3). It must be noted
that in several of the heat killed Leishmania vaccines, BCG was
a common adjuvant and the immune reaction caused by BCG
compounded the LST-based interpretation significantly. A meta-
analysis further confirmed that LST conversion may be associated
with an immune response that can provide some protection by its
ability to distinguish a subpopulation of responders to leishmanial
antigens or BCG after vaccination even though such response had
a huge variability (16–68% conversion rate) in these studies (23).
In early vaccination studies, choice of antigens in majority
of vaccine formulations related to CL as well as VL was empir-
ical. Systematic studies to identify potential vaccine antigens
against VL were undertaken more recently using proteome serol-
ogy (24), bioinformatics approaches, and reactivity with serum
from active VL cases (25, 26). Previous efforts to identify antigens
that showed protective efficacy against L. donovani infection in
experimental VL models include K26/HASPB (27), A2 (28), kine-
toplastid membrane protein-11 (29), nucleoside hydrolase (30),
cysteine proteinase B (31), and sterol 24-C-methyltransferase (25,
32). Recently, these antigens were evaluated in peripheral blood
obtained from a limited number of cases of healed VL and pre-
viously unexposed controls to test if the cytokines released in
response to Leishmania antigen can reveal markers that could pre-
dict efficacy of the six candidates (7). If the selected antigens elicit
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cellular immune responses correlating with protection or cure
(e.g., IFN-γ production in previously exposed and cured indi-
viduals) that may indicate the potential to be good candidates
for prophylactic and therapeutic vaccines. Of the cytokines tested
IFN-γ, IL-2, IL-4, IL-5, IL-10, and TNF-α, only soluble Leishma-
nia antigen-specific IFN-γ in healed VL cases showed significantly
higher secretion compared to controls (7). Interestingly, TNF-α
secretion was observed along with high IFN-γ secretion in samples
that respond to SLA (7) resembling a pattern of multifunctional
Th1 cells that correlate with protection observed against L. major
infection (33). Interestingly, KMP-11 and K26/HASPB did not
show Th1-related IFN-γ production in cured VL subjects even
though these antigens were selected on the basis of previous stud-
ies with experimental animal models that showed a protective role
for KMP-11 and K26/HASPB (27, 29). The observed discrepancy
in protective efficacy of these antigens in mouse versus human
pre-clinical studies could be due to several reasons including their
induction of CD8+ T cells, but not CD4+ cells the latter of which
have been shown to be the main source of IFN-γ in cured VL (34)
and to limitations in the measurement of responses by CD8+ T
cells (7). These studies have demonstrated the importance of com-
paring antigens for their protective efficacy and allow selection for
a future vaccine and importantly revealed the dichotomy in the
results obtained in the experimental mouse models and human
pre-clinical studies.
Previous studies with HASPB and KMP-11 as prophylactic
vaccines indicated good protection associated with the develop-
ment of CD8+ T cell responses in hamsters and isolated human
PBMCs with KMP11 (35, 36) and immunogenicity in dogs against
HASPB1 antigen (37). When these antigens were tested in a recent
study as potential therapeutic vaccines, experiments with mice
revealed that route and dose influenced the breadth and magni-
tude of the observed CD8+ T cell responses (38). For instance, the
response to the HASPB C-terminal epitope was twofold greater
in the footpad compared to subcutaneous administration (38).
Footpad vaccination induced clear and dose-dependent IgG1 and
IgG2a responses, a proxy for CD4+ T cell response but in sub-
cutaneous vaccination such response was undetectable suggesting
that route of administration as a determinant of the host response
(38). Although significant reduction in splenic parasite burdens
was observed, the failure to elicit CD8+ T cell responses indi-
cated that HASPB and KMP11 indicated that they might not
be dominant antigens in terms of CD8+ T cell recognition as
was seen in several antigen interference studies (39). However,
the reduction in the parasite burdens in the immunized mice
implied that correlation with strong CD4+ T cell responses upon
treatment with Leishmania soluble antigen may not be a neces-
sary prerequisite as suggested by the human pre-clinical studies
with these antigens. In addition, the data suggested an interesting
possibility that for an antigen to be effective as a vaccine candi-
date, it may not have to be the dominant antigen during natural
infection (38).
GENETICALLY MODIFIED LIVE ATTENUATED L. DONOVANI
AS VACCINE CANDIDATES
Though several multi-antigen recombinant protein and DNA vac-
cines have been and continue to be tested as vaccine candidates,
no effective vaccine against VL has been developed so far. In con-
trast to subunit vaccines, live attenuated parasite vaccines have
several advantages in terms of their ability to induce adaptive
immune responses relevant to protection by mimicking a nat-
ural infection without causing overt disease and likely induce
an immune response consistent with protection (40). Early live
attenuated Leishmania parasites were developed by targeted dele-
tion of dihydrofolate reductase–thymidylate synthase (DHFR-TS)
in L. major and cysteine proteases cpa and cpb in L. mexicana
(41, 42). These studies demonstrated the feasibility of using live
attenuated parasites for vaccination against CL and provided the
rationale for developing and testing several gene deletion mutants
in other Leishmania species including L. donovani subsequently.
Further, early progress demonstrated in the vaccination studies
in CL using live attenuated parasites led to identification of spe-
cific parameters to be evaluated in a discussions sponsored by
the WHO (TDR News 2005; http://www.who.int/tdr/publications/
documents/tdrnews-issue-75.pdf ).
Despite the early progress in CL vaccine studies based on
murine models of L. major infections, it is well-recognized that the
immune mechanisms mediating visceral disease in the liver and
spleen caused by L. donovani differ significantly from other species
of Leishmania causing CL and mucocutaneous disease (43, 44).
Consequently, vaccine-induced immunity required for protection
in CL versus VL is likely to differ in significant ways although cross
protection studies indicated common mechanisms of protection
(32, 45–49).
Acquisition of protective immunity following leishmanization
in cutaneous leishmaniasis (3), development of Leishmania spe-
cific Th1-type immune response, and protection against new
infection in individuals successfully cured from VL (7) and in case
of VL a complete Leishmania cDNA expression library injected
into mice was more protective than subpools of the library plas-
mids, emphasizing the idea that the whole parasite makes the
best vaccine (50). Immunization with live attenuated parasites is
likely to deliver several antigens than the limited number possi-
ble with subunit or recombinant antigens as revealed by studies
in L. major (40, 51). Recent success with irradiated Plasmod-
ium falciparum sporozoites in inducing strong protection upon
intravenous administration further demonstrates the feasibility of
using attenuated parasites as vaccine candidates (52). Relative ease
of genetic manipulation of genes allowed to produce several gene
knock out L. donovani parasite strains (5). The live attenuated
parasites organisms have the advantage of presenting a complete
antigen spectrum like in a natural infection, which may result in a
robust immunity unlike subunit vaccines that are limited in anti-
genic repertoire. The attenuated parasites persist in the host for
a limited period of time providing the immune system persistent
antigens that allowing for the generation of antigen-specific mem-
ory cells that are important for providing a protective response
following subsequent infection. Several targeted gene deletions
have been carried out to develop Leishmania-attenuated vaccine
strains. Similar to CL studies, protection against virulent challenge
was reported in experimental mouse immunization with L. dono-
vani deleted for biopterin transporter (53) A2–rel gene cluster
in L. donovani (54) SIR2 gene in L. infantum (55) and Hsp70-II
(56) as immunogens induced protection against virulent challenge
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Table 1 | Genetically modified live attenuated vaccine candidates in L. donovani complex.
Target of deletion Animal model Results of immunization Reference
Biopterin transporter, LdBT1−/− Balb/C Protective immunity, antigen-specific IFN-γ secretion Papadopoulou et al. (53)
Centrin 1, LdCen−/− Balb/C mice,
hamsters,
dogs
Protective immunity against L. donovani and L. braziliensis
challenge. Increased IFNγ, IL-2, and TNF producing cells and
IFNγ/IL-10 ratio, presence of multifunctional cells
Selvapandiyan et al.
(48), Fiuza et al. (58)
Silent information regulatory two
single allele deletion, LiSIR2±
Balb/C Protective immunity, increased antigen-specific IFNγ/IL-10 ratio Silvestre et al. (55)
Cytochrome c oxidase complex
component p27, Ldp27−/−
Balb/C 12-Week survival in host, protective immunity against L. donovani,
L. braziliensis, and L. major challenge. Increased IFNγ, IL-2, and
TNF producing cells and IFNγ/IL-10 ratio
Dey et al. (49)
Heat shock protein 70, LiHsp70−/− Balb/C Cross protection against L. major, high IgG2a relative to IgG1 Carrion et al. (56)
in BALB/c mice (Table 1). These experiments demonstrated the
potential of generating live attenuated vaccines by targeted gene
disruptions. Our laboratory has developed a L. donovani mutant
(LdCen−/−) deleted for the centrin gene. Centrin is a growth reg-
ulating gene in the protozoan parasites Leishmania. LdCen−/−
is specifically attenuated at the amastigote stage and not as the
promastigote (57). The mutant Leishmania amastigotes showed
cytokinesis arrest in the cell cycle and persisted for a short duration
in animals (mice and hamsters) or ex vivo in human macrophages
and were eventually cleared (48). Mouse immunization experi-
ments revealed that LdCen−/− can protect mice against virulent
challenge and this protection was accompanied by the induction
of robust Leishmania specific multifunctional T cell responses (48)
as was reported in previous studies that showed strong protection
against an L. major challenge (33). Immunization experiments
also revealed that intrinsic growth defect of LdCen−/− amastig-
otes allows for limited replication in the mouse as was revealed by
their clearance after a limited period. Immunization experiments
in dogs with LdCen−/− revealed that these attenuated parasites
can be inducing potent immunogenicity and early indication of
protection against virulent challenge (58). Similarly, we devel-
oped L. donovani mutant (Ldp27−/−) deleted for the p27 gene, an
essential component of cytochrome c oxidase complex involved in
oxidative phosphorylation (59). Similar to LdCen−/−, Ldp27−/−
parasites also induced Leishmania-specific multifunctional T cell
responses in mice and showed strong potential as a candidate vac-
cine (49). We have also developed L. donovani mutants deleted
for a ubiquitin-like protein in Leishmania (LdUfm1−/−) and the
processing enzyme Ufsp (LdUfsp−/−) that converts the precursor
Ufm1 into its conjugatable form (60, 61). L. donovani Ufm1 con-
jugates to and modifies the enzymes involved in β-oxidation of
fatty acids. Since the Ufm1 protein is part of a pathway involving
activities of several proteins, it is possible to create additional dele-
tion mutants deficient in multiple genes without causing additive
loss of virulence thus enhancing the safety of the live attenuated
parasites. Together, these examples of genetically altered parasites
provide opportunities for testing as live attenuated vaccine candi-
dates in pre-clinical and clinical conditions. Despite the advantages
of live attenuated parasites as vaccines, there are considerable chal-
lenges. A major concern with live attenuated vaccines is the risk
of reversion to a virulent parasite. Hence, biomarkers of safety
are essential to assess the genetic and physiological traits of the
organism to assess stability of the attenuated parasites in addi-
tion to biomarkers of efficacy that are just as important to any
kind of anti-Leishmania vaccine. Several issues regarding the live
attenuated vaccines must be overcome including safety, genetic
stability, lack of transmissibility, limited persistence, and condi-
tions of cryopreservation in order for these vaccines to be used
in human trials (62). In addition, growing the attenuated organ-
isms in media containing serum of bovine origin constitutes a
possible safety risk due to BSE-related hazard. Our recent stud-
ies have shown that the live attenuated L. donovani parasites can
be grown in serum free media (63). The presence of antibiotic
markers in the live attenuated organisms can be potential safety
concern. Recent clinical trials for treating lung cancer and glioblas-
toma with tumor cell vaccines or retroviral vectors containing
Neor and Hygr markers that confer resistance against neomycin
and hygromycin suggest that these markers may be permissible in
clinical trials (64, 65). However, recent developments in genome
engineering methods including use of zinc finger nucleases, tran-
scription activator-like effector nucleases might be pertinent for
developing marker free live attenuated Leishmania parasites as was
the use of Tn5 transposon or thymidine kinase-based antibiotic
marker removal (66–69). The ability to create marker free attenu-
ated mutants might also be helpful in creating Leishmania parasites
lacking multiple genes thus limiting the probability of reversion
to virulence due to mutations in secondary loci as observed in
lpg2−/− in L. major (70). Similarly, infection experiments under
immunosuppressive conditions to show limited persistence and
sand fly infections post-immunization to show lack of transmis-
sibility might be necessary for demonstrating the safety of live
attenuated Leishmania parasites. Our preliminary experiments to
investigate transmissibility by sand flies have shown that the live
attenuated L. donovani parasites (LdCen−/− and Ldp27−/−) do
not establish an infection in sand flies (Dey et al., unpublished).
IMMUNOLOGY OF HUMAN VL
The immunopathology of VL has been extensively studied in
experimental mouse model, dog model, and to a limited extent
in humans. It has long been established that protection against
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Leishmania is derived predominantly from T cell-mediated immu-
nity with both Th1- and Th2-associated cytokines contributing
to vaccine-induced resistance (71). Even though the correlates of
immunity to human VL are not fully understood, the protection
requires antigen-specific CD+4 and CD+8 T cell responses (72).
PBMCs from active VL patients typically do not proliferate or pro-
duce IFN-γ in response to Leishmania antigen where as PBMCs
from cured VL cases do proliferate [(73), Avishek et al., unpub-
lished data]. Recent studies have clarified that human VL is not
associated with Th2-biased responses dominated by IL-4 and or
IL-13 but produce elevated serum IL-1, IL-6, IL-8, IL-12, IL-15,
IP-10, IFN-γ, and TNFα (74, 75). The role of IL-10 in promoting
pathology of VL has long been demonstrated in human studies.
This is primarily accomplished by turning macrophages unre-
sponsive to activation signals. DCs are important for initiating
immunity and further modifying the immune response. Secre-
tion of cytokines by DCs strongly influences the outcome of T
cell responses. Stimulation of DCs to produce IL-12 drives cre-
ation of antigen-specific IFN-γ secreting Th1-type CD4 and CD8
cells that aid in resolution of infection (76). Several human stud-
ies indicated that IFN-γ secretion is the biomarker for protection
even though both VL and CL can progress despite the presence of
a Th1-type of response. IL-10 expression is the only other marker
that has been consistently shown to negatively correlate with the
protection. Elevated serum levels of IL-10, IL-6, and IL-8 in serum
have been shown to be associated with active disease (73).
Poor understanding of the mechanism of immune protection
has thus impaired development of effective vaccine against human
VL so far. This is in many respects paralleled by attempts at devel-
oping a vaccine against malaria. More recently, results from the
clinical trials with RTS,S/AS01 in the infants have underlined the
importance of biomarkers of efficacy. Efficacy of RTS,S/AS01 was
only 26% against sever malaria (9). Absence of knowledge about
the nature of adaptive immune responses in certain protected
population in malaria endemic areas and whether such immuno-
logical correlates of protection can be mimicked by vaccination
still remain unanswered. The protection observed only in small
fraction of infants suggests that it is important to determine which
vaccine elicited responses are necessary for such protection (77).
Since typical clinical trials can last for several years, absence of
knowledge on biomarkers of protection can considerably impede
the progress of vaccine development. This is reflected by the lim-
ited success rate (22%) observed in vaccine development (78).
Comprehensive analysis of antibodies, cytokines, immune cells,
and whole-genome transcription to identify key host responses
associated with an effective protection would be necessary to reveal
those answers.
SYSTEMS BIOLOGICAL APPROACHES IN VACCINE-INDUCED
IMMUNITY
Majority of the currently licensed vaccines have mostly developed
empirically, and protection by these vaccines is generally conferred
by antigen-specific antibodies, which prevent infection. Many viral
vaccines, such as the live attenuated vaccines, work by mimicking
pathogens, to stimulate lasting and protective immunity in the
host (79). Only recently, the immune mechanisms underlying the
protection are beginning to be understood in the otherwise empir-
ically developed viral vaccines. Recent technological advances in
molecular genetics, molecular and cellular immunology, structural
biology, bioinformatics, computational biology, nanotechnology,
formulation technologies, and systems biology have facilitated
new developments in antigen discovery/design, adjuvant discov-
ery, and immune monitoring that offer substantial potential for
discovering new biomarkers of protective immunity, and identify
the limitations of animal models for screening and prioritizing
human vaccines (80). Recent progress in understanding how the
innate immune system recognizes microbial stimuli and regulates
adaptive immunity is being applied to vaccine discovery in what
is termed “systems vaccinology” (81). Systems vaccinology is an
offshoot of systems biology for which tools of a number of high-
throughput technologies including DNA microarrays, RNA-seq,
protein arrays, deep sequencing, mass spectrometry along with
sophisticated computational tools have been originally developed
(81). Together, these tools enable system-wide unbiased molec-
ular measurements, which can then be used to reconstruct the
perturbations in the immune networks (82).
The tools of systems biology were first applied for the highly
effective yellow fever vaccine YF-17D, which is a live attenuated
virus. Yellow fever vaccine has been one of the most success-
ful vaccines known. Past immunological studies have revealed
that YF-17D induces neutralizing antibodies, cytotoxic T cells and
Th1/Th2 cells, and signal via Toll-like receptors 2, 7, 8, and 9 on
subsets of dendritic cells (83). Querec et al. (11) and Gaucher
et al. (84) first applied systems biological approaches in evaluating
immune responses to vaccination to discern new and fundamen-
tal insights about the workings of the immune system by detailed
study of innate and adaptive immune responses to vaccination
(Yellow Fever Vaccine) in humans. When the PBMCs from the
vaccinated and control groups were tested in human microar-
ray hybridization experiments, results revealed that genes of the
antiviral type I interferon pathway, complement pathway, and
inflammasome were induced 3–7 days after vaccination, concomi-
tant with the development of the adaptive immune response. In
addition, a broad spectrum of gene regulations for innate sensing,
including TLR7, RIG-I, MDA5, and LGP2, and for innate signal-
ing, including JUN, STAT1, IRF7, and RNF36, was also observed.
Analysis of immune networks revealed that it is possible to pre-
dict titers of neutralizing antibodies by the early gene expression
signatures.
Later studies with seasonal influenza model using systems biol-
ogy approaches compared immune responses to a live attenuated
virus vaccine, or a trivalent-inactivated vaccine (12). This com-
parison revealed important differences between the live attenuated
versus trivalent-inactivated vaccines. The live attenuated vaccine
induced the expression of several interferon-related genes, com-
mon to live viral vaccines where as, the inactivated vaccine, induced
genes highly expressed in plasma B cells. Such comparative analy-
sis of gene expression in human microarrays in the first week of
vaccination allowed prediction of antibody responses in the vac-
cines based on the expression of markers such as the receptor gene
for B cell growth factor BLyS (12). This clearly demonstrated that
analysis of early transcriptomic profiles from the peripheral blood
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can be used in identifying novel immune networks and also predict
vaccine efficacy.
The gene expression profiles once obtained can also be utilized
to identify if the correlates of protection are universally applicable.
For instance, the metabolic changes of the aging body, including
the increased presence of apoptotic cells and of oxidative stress
induce the immune system to change its “quiescent” state to a dif-
ferent, often higher level of basal activation [reviewed in Ref. (85)].
Similarly, the role of sex hormones in affecting the vaccine-induced
immunity is not often studied. A meta-analysis of the yellow fever
vaccine study revealed substantially higher expression signatures
in the toll-like receptor–interferon signaling in women compared
to men (86). Similar studies with influenza vaccine revealed an
immunosuppressive role for testosterone in influenza vaccination.
Unexpectedly, this immunosuppression was linked to genes that
participate in lipid metabolism including leukotriene A4 hydro-
lase, revealing the power of systems analysis (87). The main appeal
of using systems biology approaches to examine vaccine-induced
immunity is the ability to study early responses in peripheral
blood by comparing genes and pathways induced before/after
immunization. This paradigm can be applied to compare effi-
cacy of different vaccine formulations including live attenuated
parasite vaccines, recombinant antigen vaccines if knowledge of
biomarkers of protection is available.
Since immune cells migrate through the blood stream between
lymph nodes, spleen, and peripheral tissues obtaining meaningful
information of an immune response from this dynamic mix of cells
remains a complex challenge. Several attempts have been made at
decomposing the gene expression profile from a heterogeneous
mix of cells into that of respective cell types based on unique gene
expression profiles independently obtained from a pure cell pop-
ulation such as monocytes, lymphocytes, neutrophils, eosinophils,
and basophils (88).
With the development of genomic and proteomic tools along
with advances in computational approaches, global profiling of
cellular states in terms of gene and protein expression has been
applied to study a broad range of immunological phenomena.
These approaches have been used to study T cell activation sig-
natures (89, 90), blood cell states in patients with autoimmunity
(91), and the responses of host cells to HCV infection (92).
Even though the approaches outlined here can provide funda-
mental insights into the immune responses to complex pathogens,
it must be noted that so far only viral vaccines were studied. In most
such cases, protection is mediated by antibodies whereas clear-
ance of parasitic pathogens needs predominantly cell-mediated
immunity. The role of antibody responses in protection is at best
inconclusive in human leishmaniasis (73). In addition, it is con-
ceivable that parasites engage with human immunity in multiple
levels as is evidenced by immune suppression in humans with
active VL. Computational approaches developed for the analysis
of innate immunity point to the possibility of such analysis in
human VL (93).
CONCLUSION
A major shortcoming in the vaccine development is the inade-
quate predictive power of the early immune responses mounted
in the host against the vaccines. Also, for the live attenuated para-
site vaccines, the primary barrier against widespread use remains
safe in terms of avirulence of the parasites in host. Therefore,
understanding of the pathogenesis of live attenuated parasites
such as LdCen−/− in human PBMC in different clinical groups
will provide valuable information regarding avirulence of these
parasites and efficacy in terms of immune- and non-immune-
related responses prior to the evaluation in human trials. Recent
influenza vaccine studies substantiated that the role of non-
immune parameters in protective immunity is generally under
appreciated and often missed in conventional vaccine studies that
measure only immunological parameters. Obtaining such infor-
mation via systems biology approaches, as has been applied to
study viral vaccines, will enable us to understand how vaccine-
induced responses are coordinately regulated in healthy, asymp-
tomatic infected individuals, and individuals recovered from VL.
This will provide information regarding correlates of protection as
well as biomarkers of safety and enable identification of immune
and non-immune predictors hitherto unidentified to Leishmania
antigens or live attenuated vaccine candidates in the human cells
and might be useful in shaping the final vaccine formulation in
the clinical trials. Studies comparing expression profiles of PBMCs
from bonafide asymptomatic carriers with those that acquired
protective immunity following clinical cure will likely provide bio-
markers other than the IFN-γ secretion as is currently practiced.
Understanding of immune modulators that confer protection in
VL can lead to new targets for immune therapy.
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